BRAND FIRMS MAY SEEK TO DELAY GENERIC COMPETITION THROUGH NONLISTED PATENTS

Generic Line
KEYWORDS FDA / HatchWaxman
A A

While reforms to the Hatch-Waxman Act aim to cut down on abuses of the drug patent system, a provision in the law may still let brand firms delay generic competition by simply not listing all of their patents in the FDA’s Orange Book.

To View This Article:

Login

Subscribe To Generic Line

Buy This Article Now

Add this article to your cart for $10.00